Alaunos receives Nasdaq deficiency notice for equity below $2.5M minimum; 45 days to submit plan

Alaunos Therapeutics, Inc.

Stockholders' equity of $2.063M as of Dec 31, 2024, falls short of Nasdaq's $2.5M minimum under Rule 5550(b)(1).
Company has 45 days from Apr 7, 2025 to submit a compliance plan; if accepted, may have up to 180 days to cure.
Nasdaq also removed the one-year Panel Monitor that had been in place since February 2024.
The deficiency notice does not immediately affect listing, but non-compliance could lead to delisting.
Company intends to evaluate options and submit a plan to regain compliance within the allowed timeframe.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.